Neuronetics Stock Today
| STIM Stock | USD 1.55 0.27 14.84% |
PerformanceWeakest
| Odds Of DistressRisky
|
Neuronetics is selling at 1.55 as of the 5th of February 2026; that is 14.84 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.36. Neuronetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 7th of November 2025 and ending today, the 5th of February 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 28th of June 2018 | Category Healthcare | Classification Health Care |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. The company has 68.49 M outstanding shares of which 7.16 M shares are at this time shorted by private and institutional investors with about 4.75 trading days to cover. More on Neuronetics
Moving against Neuronetics Stock
| 0.85 | HAE | Haemonetics Earnings Call Today | PairCorr |
| 0.59 | 2DR | Inspire Medical Systems Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Neuronetics Stock Highlights
| CEO President | Keith Sullivan | ||||
| Old Name | ETFS 1x Daily Short Tin ETC | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsNeuronetics utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Neuronetics' leverage profile, showing how much of Neuronetics' resources are funded through borrowing.
| |||||
Neuronetics (STIM) is traded on NASDAQ Exchange in USA and employs 716 people. Neuronetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 124.64 M. Neuronetics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 68.49 M outstanding shares of which 7.16 M shares are at this time shorted by private and institutional investors with about 4.75 trading days to cover.
Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Neuronetics Probability Of Bankruptcy
Ownership AllocationNeuronetics maintains a total of 68.49 Million outstanding shares. Over half of Neuronetics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neuronetics Ownership Details
Neuronetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2025-06-30 | 442.9 K | |
| State Street Corp | 2025-06-30 | 427.9 K | |
| Two Sigma Investments Llc | 2025-06-30 | 367.8 K | |
| Boothbay Fund Management, Llc | 2025-06-30 | 337 K | |
| Ubs Group Ag | 2025-06-30 | 318 K | |
| Northern Trust Corp | 2025-06-30 | 275.4 K | |
| Awm Investment Company Inc | 2025-06-30 | 245.9 K | |
| Hightower Advisors, Llc | 2025-06-30 | 160 K | |
| Two Sigma Advisers, Llc | 2025-06-30 | 157.4 K | |
| Vanguard Group Inc | 2025-06-30 | 2.7 M | |
| Blackrock Inc | 2025-06-30 | 2.2 M |
Neuronetics Historical Income Statement
Neuronetics Stock Against Markets
Neuronetics Corporate Management
| MBA CMA | Chief Officer | Profile | |
| Lisa MetznerRosas | Senior Officer | Profile | |
| Andrew Macan | Gen VP | Profile | |
| Claire Sears | VP Marketing | Profile | |
| Rick Grubbs | Senior Accounts | Profile | |
| Cory Anderson | Senior Clinical | Profile | |
| Kara Thornton | VP Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuronetics diversify its offerings? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuronetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
Neuronetics's market price often diverges from its book value, the accounting figure shown on Neuronetics's balance sheet. Smart investors calculate Neuronetics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Neuronetics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.